OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2. Oxford, United Kingdo ...

New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

NEW YORK -- New York City Mayor Eric Adams pleaded innocent Friday to federal bribery charges, rejecting claims that he accepted overseas travel, campaign cash and other perks from foreign interests ...